In contrast, our previous studies in pancreatic, lung and colon cancer cells show that C-DIM/NR4A1 antagonists act on nuclear NR4A1 and do not induce nuclear export of the receptor [confirmed in RCC cells (Fig 3)] and these compounds also decrease NR4A1-dependent transactivation [14–17]. This evidence concerns the gene NR4A1 and renal cell carcinoma.